Amryt Pharma (AMYT) Stock Price, News & Analysis

Company Overview

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

Key Stats

• Today's Range: $14.63 to $14.76
• 50-Day Range: $14.55 to $14.70
• 52-Week Range: $6.41 to $14.77
• Volume: 2.39 million shs
• Average Volume: 757,360 shs
• Market Capitalization: $940.21 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AMYT Stock Analysis - Frequently Asked Questions

How were Amryt Pharma's earnings last quarter?

Amryt Pharma plc (NASDAQ:AMYT) released its earnings results on Thursday, November, 5th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.73) by $0.66. The firm earned $49.33 million during the quarter. Amryt Pharma had a positive trailing twelve-month return on equity of 1.70% and a negative net margin of 8.19%.

What other stocks do shareholders of Amryt Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Amryt Pharma investors own include Alibaba Group (BABA), Dynavax Technologies (DVAX), Advanced Micro Devices (AMD), Teladoc Health (TDOC), NIO (NIO), Tesla (TSLA).

Company Calendar

• Last Earnings: 11/05/2020
• Today: 7/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:AMYT
• CIK: 1783010
• Web: www.amrytpharma.com
• Phone: 353-1518-0200
• Fax: N/A
• Employees: 2,020
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $1 million
• Net Margins: -8.19%
• Pretax Margin: -0.56%
• Return on Equity: 1.70%
• Return on Assets: 0.75%

Debt

• Debt-to-Equity Ratio: 0.64
• Current Ratio: 1.57
• Quick Ratio: 0.94

Sales & Book Value

• Annual Sales: $222.54 million
• Price / Sales: 4.22
• Cash Flow: $0.98 per share
• Price / Cash Flow: 14.98
• Book Value: $5.58 per share
• Price / Book: 2.63

Miscellaneous

• Outstanding Shares: 63,960,000
• Free Float: 60,343,000
• Market Cap: $940.21 million
• Optionable: Not Optionable
• Beta: 0.84